Rachel Davis, MD
Ophthalmic Plastic and Reconstructive Surgery · Brecksville, OHNPI 1487018131
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,293 of the $27,187 with a category attached, or 85.7%. Amgen accounts for 95.5% of it on its own, with 15 other manufacturers making up the rest.
Across 93 payments — averaging $292.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- Alcon$325
- AbbVie$273
- Glaukos Corporation$115
- Mallinckrodt Enterprises LLC$104
- Novartis$102
- plus $309 from 10 others
What the payments were for
- Consulting fees$8503%
- Speaking & faculty fees$23,29386%
- Travel & lodging$2811%
- Food & beverage$2,76410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 55 | $25,959 |
| Alcon | 10 | $325 |
| AbbVie(2 entities) | 10 | $273 |
| Glaukos Corporation | 1 | $115 |
| Mallinckrodt Enterprises LLC | 1 | $104 |
| Novartis | 1 | $102 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $82 |
| Oyster Point Pharma, Inc. | 3 | $69 |
| Bausch & Lomb Americas Inc. | 2 | $38 |
| Ocular Therapeutix, Inc. | 1 | $25 |
| Merz Pharmaceuticals, LLC | 1 | $20 |
| Johnson & Johnson Vision Care, Inc. | 1 | $18 |
| Tarsus Pharmaceuticals, Inc. | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
| Omeros Corporation | 1 | $13 |
| Ivantis, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 174 | $1,777 |
| Methylprednisolone | 199 | $1,325 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 73 | $834 |
| Doxycycline Monohydrate | 19 | $730 |
| Doxycycline Hyclate | 11 | $223 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Brecksville
- Raymond ChoColumbus$23K
- Courtney KauhGahanna$5K
- Daniel StrakaWorthington$2K
- John KuneshDayton$1K
- Walter HartelDayton$724
- Catherine HwangCleveland$474
- Julian PerryCleveland$333
- Rosa Balcells GonzalezBlue Ash$309
- Mary CravenColumbus$95
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.